BACKGROUND: This article reports, the @entity1370 according to 6- versus 12-month durations of adjuvant trastuzumab in PHARE randomised trial (NCT00381901). @entity1 AND METHODS: Cardiac follow-up and Left Ventricular Ejection Fraction (LVEF) assessment by echocardiography or multigated acquisition scan were performed every 3months while @entity1 received trastuzumab and after completion of treatment over the first 2years and every 6months afterwards. The primary cardiac end-point was @entity712 ( @entity712 ) defined as New York Heart Association (NYHA) class III or IV. The secondary @entity299 were: @entity299 , @entity299 defined by NYHA class I and II; LVEF decreases, cardiac recoveries. The cardiac subcommittee reviewed @entity299 and assessed if @entity1 had favourable outcomes or not on the basis of trends from LVEF measurements. RESULTS: Among 3380 @entity1 the cardiac dysfunction assessment included 14,055 and 13,218 LVEF measurements in the 12- and 6-month arms. The overall incidences of @entity712 were 0.65% (11/1690) and 0.53% (9/1690) in the 12 and 6month arms, respectively (p>0.05). @entity299 occurred in 5.9% (100/1690) and 3.4% (58/1690) of @entity1 in the 12 and 6month arms, respectively (p=0.001). Recoveries were observed for the majority @entity1 and 0.79% (27/3380) of @entity1 experienced an unfavourable cardiac outcome. CONCLUSION: PHARE confirm that the incidence of @entity299 remains low and mostly reversible after trastuzumab. Identification at baseline of cardiac risk categories of @entity1 should be of interest to provide an optimal adaptation of adjuvant modalities and a shorter duration might be an option.

XXXX events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity712 :: ('MESH:D006333', 'Disease') :: ['Cardiac Heart Failure', 'CHF'] @entity1370 :: ('MESH:D066126', 'Disease') :: ['cardiac toxicity'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac dysfunctions', 'Cardiac dysfunction', 'cardiac events', 'cardiac end-points']
@entity1370 :: (MESH:D066126,Disease) :: ['Cardiac toxicity']
